PDF(Pubmed)
Abstract：
The relationships of the rs17782313 polymorphism near melanocortin 4 receptor gene (MC4R) and the rs8192678 polymorphism in peroxisome proliferator-activated receptor gamma coactivator 1 alpha gene (PGC1α) with metabolic abnormalities have been explored in many populations around the world, but the findings were not all consistent and sometimes even a bit contradictory.
Electronic databases including Medline, Scopus, Embase, Web of Science, CNKI and Google Scholar were checked for studies that met the inclusion criteria. Data were carefully extracted from eligible studies. Standardized mean differences (SMDs) were calculated by using a random-effects model to examine the differences in the indexes of obesity, glucometabolic disorder and dyslipidemia between the genotypes of the rs17782313 and rs8192678 polymorphisms. Cochran\'s Q-statistic test and Begg\'s test were employed to identify heterogeneity among studies and publication bias, respectively.
Fifty studies (58,716 subjects) and 51 studies (18,660 subjects) were respectively included in the pooled meta-analyses for the rs17782313 and rs8192678 polymorphisms. The C-allele carriers of the rs17782313 polymorphism had a higher average level of body mass index (SMD = 0.21 kg/m2, 95% confidence interval [95% CI] = 0.12 to 0.29 kg/m2, p < 0.001), waist circumference (SMD = 0.14 cm, 95% CI = 0.06 to 0.23 cm, p < 0.001) and blood glucose (SMD = 0.09 mg/dL, 95% CI = 0.02 to 0.16 mg/dL, p = 0.01) than the TT homozygotes. Regarding the rs8192678 polymorphism, no significant associations with the indexes of obesity, glucometabolic disorder and dyslipidemia were detected. However, significant correlations between the rs8192678 polymorphism and multiple glucometabolic indexes were observed in subgroup analyses stratified by sex, age, ethnicity and health status.
The meta-analysis demonstrates that the C allele of the MC4R rs17782313 polymorphism confers a higher risk of obesity and hyperglycemia, and the PGC1α rs8192678 polymorphism is weakly correlated with glucometabolic disorder. These findings may partly explain the relationships between these variants and diabetes as well as cardiovascular disease.
https://www.crd.york.ac.uk/prospero/, identifier CRD42022373543.
Electronic databases including Medline, Scopus, Embase, Web of Science, CNKI and Google Scholar were checked for studies that met the inclusion criteria. Data were carefully extracted from eligible studies. Standardized mean differences (SMDs) were calculated by using a random-effects model to examine the differences in the indexes of obesity, glucometabolic disorder and dyslipidemia between the genotypes of the rs17782313 and rs8192678 polymorphisms. Cochran\'s Q-statistic test and Begg\'s test were employed to identify heterogeneity among studies and publication bias, respectively.
Fifty studies (58,716 subjects) and 51 studies (18,660 subjects) were respectively included in the pooled meta-analyses for the rs17782313 and rs8192678 polymorphisms. The C-allele carriers of the rs17782313 polymorphism had a higher average level of body mass index (SMD = 0.21 kg/m2, 95% confidence interval [95% CI] = 0.12 to 0.29 kg/m2, p < 0.001), waist circumference (SMD = 0.14 cm, 95% CI = 0.06 to 0.23 cm, p < 0.001) and blood glucose (SMD = 0.09 mg/dL, 95% CI = 0.02 to 0.16 mg/dL, p = 0.01) than the TT homozygotes. Regarding the rs8192678 polymorphism, no significant associations with the indexes of obesity, glucometabolic disorder and dyslipidemia were detected. However, significant correlations between the rs8192678 polymorphism and multiple glucometabolic indexes were observed in subgroup analyses stratified by sex, age, ethnicity and health status.
The meta-analysis demonstrates that the C allele of the MC4R rs17782313 polymorphism confers a higher risk of obesity and hyperglycemia, and the PGC1α rs8192678 polymorphism is weakly correlated with glucometabolic disorder. These findings may partly explain the relationships between these variants and diabetes as well as cardiovascular disease.
https://www.crd.york.ac.uk/prospero/, identifier CRD42022373543.
摘要：
■已经在许多人群中探索了黑皮质素4受体基因（MC4R）附近的rs17782313多态性和过氧化物酶体增殖物激活受体γ共激活因子1α基因（PGC1α）中的rs8192678多态性与代谢异常的关系。世界，但是研究结果并不一致，有时甚至有点矛盾。
■电子数据库，包括Medline，Scopus,Embase,WebofScience,对CNKI和谷歌学者进行了符合纳入标准的研究检查。从符合条件的研究中仔细提取数据。通过使用随机效应模型计算标准化平均差异（SMD）来检查肥胖指标的差异，rs17782313和rs8192678多态性基因型之间的糖代谢紊乱和血脂异常。采用Cochran的Q统计检验和Begg检验来识别研究和发表偏倚之间的异质性。分别。
■50项研究（58,716名受试者）和51项研究（18,660名受试者）分别包括在rs17782313和rs8192678多态性的汇总荟萃分析中。rs17782313多态性的C等位基因携带者的平均体重指数较高（SMD=0.21kg/m2，95％置信区间[95％CI]=0.12至0.29kg/m2，p<0.001），腰围（SMD=0.14cm，95%CI=0.06至0.23厘米，p<0.001）和血糖（SMD=0.09mg/dL，95%CI=0.02至0.16mg/dL，p=0.01）比TT纯合子。关于rs8192678多态性，与肥胖指数没有显著关联，检测到糖代谢紊乱和血脂异常。然而,在按性别分层的亚组分析中观察到rs8192678多态性与多种糖代谢指标之间的显着相关性，年龄,种族和健康状况。
■荟萃分析表明，MC4Rrs17782313多态性的C等位基因赋予了更高的肥胖和高血糖风险，PGC1αrs8192678多态性与糖代谢紊乱弱相关。这些发现可能部分解释了这些变异与糖尿病以及心血管疾病之间的关系。
■https://www.crd.约克。AC.英国/普华永道/，标识符CRD42022373543。
■电子数据库，包括Medline，Scopus,Embase,WebofScience,对CNKI和谷歌学者进行了符合纳入标准的研究检查。从符合条件的研究中仔细提取数据。通过使用随机效应模型计算标准化平均差异（SMD）来检查肥胖指标的差异，rs17782313和rs8192678多态性基因型之间的糖代谢紊乱和血脂异常。采用Cochran的Q统计检验和Begg检验来识别研究和发表偏倚之间的异质性。分别。
■50项研究（58,716名受试者）和51项研究（18,660名受试者）分别包括在rs17782313和rs8192678多态性的汇总荟萃分析中。rs17782313多态性的C等位基因携带者的平均体重指数较高（SMD=0.21kg/m2，95％置信区间[95％CI]=0.12至0.29kg/m2，p<0.001），腰围（SMD=0.14cm，95%CI=0.06至0.23厘米，p<0.001）和血糖（SMD=0.09mg/dL，95%CI=0.02至0.16mg/dL，p=0.01）比TT纯合子。关于rs8192678多态性，与肥胖指数没有显著关联，检测到糖代谢紊乱和血脂异常。然而,在按性别分层的亚组分析中观察到rs8192678多态性与多种糖代谢指标之间的显着相关性，年龄,种族和健康状况。
■荟萃分析表明，MC4Rrs17782313多态性的C等位基因赋予了更高的肥胖和高血糖风险，PGC1αrs8192678多态性与糖代谢紊乱弱相关。这些发现可能部分解释了这些变异与糖尿病以及心血管疾病之间的关系。
■https://www.crd.约克。AC.英国/普华永道/，标识符CRD42022373543。
